Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 2866 AL 2880

Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease

Ghosh S, Durgvanshi S, Agarwal S, Raghunath M, Sinha JK.

Curr Neuropharmacol. 2020;18(9):883-903. doi: 10.2174/1570159X18666200429011823.

Pharmacological approaches to mitigate neuroinflammation in Alzheimer's disease

Uddin MS, Kabir MT, Mamun AA, Barreto GE, Rashid M, Perveen A, Ashraf GM.

Int Immunopharmacol. 2020 Jul;84:106479. doi: 10.1016/j.intimp.2020.106479. Epub 2020 Apr 27.

Tau immunotherapies: Lessons learned, current status and future considerations

Sandusky-Beltran LA, Sigurdsson EM.

Neuropharmacology. 2020 Sep 15;175:108104. doi: 10.1016/j.neuropharm.2020.108104. Epub 2020 Apr 28.

The current landscape in Alzheimer's disease research and drug discovery

Devenish SRA.

Drug Discov Today. 2020 Jun;25(6):943-945. doi: 10.1016/j.drudis.2020.04.002. Epub 2020 Apr 28.

Phenolic lipids as unique bioactive compounds: a comprehensive review on their multifunctional activity toward the prevention of Alzheimer's disease

Meshginfar N, Tavakoli H, Dornan K, Hosseinian F.

Crit Rev Food Sci Nutr. 2021;61(8):1394-1403. doi: 10.1080/10408398.2020.1759024. Epub 2020 May 2.

Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease

Joshi A, Wang DH, Watterson S, McClean PL, Behera CK, Sharp T, Wong-Lin K.

Neuropharmacology. 2020 Sep 1;174:108118. doi: 10.1016/j.neuropharm.2020.108118. Epub 2020 May 4.

Photobiomodulation for Alzheimer's Disease: Translating Basic Research to Clinical Application

Enengl J, Hamblin MR, Dungel P.

J Alzheimers Dis. 2020;75(4):1073-1082. doi: 10.3233/JAD-191210.

A Systematic Review of Current Progresses in the Nucleic Acid-Based Therapies for Neurodegeneration with Implications for Alzheimer's Disease

Ghaffari M, Sanadgol N, Abdollahi M.

Mini Rev Med Chem. 2020;20(15):1499-1517. doi: 10.2174/1389557520666200513122357.

Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist

Ribaudo G, Ongaro A, Zagotto G, Memo M, Gianoncelli A.

ACS Chem Neurosci. 2020 Jun 17;11(12):1726-1739. doi: 10.1021/acschemneuro.0c00244. Epub 2020 May 28.

Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: a case report

Mimura Y, Kurose S, Takata T, Tabuchi H, Mimura M, Funayama M.

BMC Neurol. 2020 May 13;20(1):183. doi: 10.1186/s12883-020-01769-2.

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

Novak G, Streffer JR, Timmers M, Henley D, Brashear HR, Bogert J, Russu A, Janssens L, Tesseur I, Tritsmans L, Van Nueten L, Engelborghs S.

Alzheimers Res Ther. 2020 May 14;12(1):58. doi: 10.1186/s13195-020-00614-5.

Novel Anti-Alzheimer's Therapeutic Molecules Targeting Amyloid Precursor Protein Processing

Uddin MS, Kabir MT, Jeandet P, Mathew B, Ashraf GM, Perveen A, Bin-Jumah MN, Mousa SA, Abdel-Daim MM.

Oxid Med Cell Longev. 2020 Apr 29;2020:7039138. doi: 10.1155/2020/7039138. eCollection 2020.

M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?

Scarpa M, Hesse S, Bradley SJ.

Adv Pharmacol. 2020;88:277-310. doi: 10.1016/bs.apha.2019.12.003. Epub 2020 Jan 27.

Polygala tenuifolia: a source for anti-Alzheimer's disease drugs

Deng X, Zhao S, Liu X, Han L, Wang R, Hao H, Jiao Y, Han S, Bai C.

Pharm Biol. 2020 Dec;58(1):410-416. doi: 10.1080/13880209.2020.1758732.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias